A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest. Beyond a visit to the Pharmalot ancestors, we plan to catch up on reading, chores, and naps. And what about you? This may be a good time to enjoy the great outdoors. You could plan a summer getaway. Or simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. And if this applies, remember to call Dad. See you soon …

After a prolonged row, the U.K.’s National Institute for Health and Care Excellence and Roche have finally struck a deal for routine use of the Kadcyla breast cancer drug on the National Health Service, The Guardian writes. Details were not disclosed, but Roche will offer a discount. Until now, the drug has only been covered by the Cancer Drugs Fund, which finances drugs not routinely paid for on the NHS.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy